Navigation Links
Trovagene and Strand Life Sciences Plan Collaboration to Validate and Offer Urine-Based HPV Screening Test in India and South Asia

SAN DIEGO, June 7, 2012 /PRNewswire/ -- Trovagene, Inc. (Nasdaq:  TROV), a developer of trans-renal molecular diagnostics, and Strand Life Sciences Pvt Ltd., of Bangalore, India, have entered into a Memorandum of Understanding (MOU) to license and validate Trovagene's proprietary Human Papillomavirus (HPV) urine test and High Risk HPV DNA Assay for clinical diagnostic and carrier screening use in India and countries in the South Asian Association for Regional Cooperation ("SAARC").

"The potential to use urine, an easily obtained and stable testing sample, for high risk HPV carrier screening across medically underserved areas is very promising," remarks Vijay Chandru, PhD, chairman and chief executive officer of Strand Life Sciences. "We are pleased to be working with Trovagene, a leader in this field, on this important project that has the potential to make HPV screening broadly available in the region and to become a new standard of care."

Strand intends to establish Trovagene's proprietary HPV assay technology in its molecular diagnostic laboratory operations and to perform extended analytical and clinical validation studies in its target markets.  The initial validation will assess the diagnostic accuracy using urine as a specimen for HPV testing in various stages of disease progression, ranging from low grade erosions to established cervical cancer.  This will be compared to standard cytology and PAP staining as well as a commercially available standard molecular test for the detection of HPV DNA from cervical smears.

"The concept of carrier screening for high risk HPV status is one that may change the way the risk for cervical cancer and other HPV-related cancers is detected," states Antonius Schuh, Ph.D., chief executive officer of Trovagene. "In the majority of high risk HPV carriers the virus clears spontaneously. These individuals do not need to undergo more invasive diagnostic procedures. A urine test holds the promise to identify individuals free of high-risk HPV in an entirely non-invasive fashion."

Strand also intends to explore and validate the clinical utility of HPV DNA testing as a risk indicator and pathological cause of oral cancer in buccal swabs, biopsies and saliva/sputum specimens.

About Strand Life Sciences Pvt Ltd.

Strand Life Sciences – "Strand" has pioneered the practice of scientific intelligence in life and health sciences. Strand's segue into the life sciences was through products and services for research biologists, chemists, and toxicologists that combine advanced visualization, predictive systems modeling, data integration and scientific context management. Strand was spun off by faculty of the Indian Institute of Science, the first sanctioned example of academic entrepreneurship in India. Strand has a strong portfolio of intellectual property which include products such as GeneSpring, Avadis NGS, the Virtual Liver Platform and several novel biomarkers. Over 2000 research laboratories worldwide (about 30% of global market share) are licensees of Strand's technology products as are several leading Pharmaceutical and Biotechnology companies. Strand's talent pool, of around 150 "best in class" computer scientists and biologists, has repeatedly demonstrated capabilities to define and deliver path breaking products and solutions.

Strand's state-of-the-art Research and Development Center in Bangalore includes a 30,000 square feet informatics facility space in Bangalore has dedicated customer work areas with electronic access systems and exclusive network infrastructure to ensure conformance to the highest level of data and information security. Strand and its partner Ganit Labs share additional 10,000 square feet of laboratory space with state of the art clinical genomics capabilities and capacity for pre-clinical toxicology assays of lead compounds.

For more information, visit or e-mail us at

About Trovagene, Inc.

Headquartered in San Diego, California, Trovagene is developing its patented technology for the detection of transrenal DNA and RNA, short nucleic acid fragments, originating from normal and diseased cell death that cross the kidney barrier and can be detected in urine.

Trovagene has a dominant patent position as it relates to transrenal molecular testing. It has U.S. and European patent applications and issued patents that cover testing for HPV and other infectious diseases, cancer, transplantation, prenatal and genetic testing. In addition, it owns worldwide rights to nucleophosmin-1 (NPM1), an informative biomarker for acute myeloid leukemia (AML) and mutations in the SF3B1 gene, which have been shown to be associated with chemotherapy response in CLL (chronic lymphocytic leukemia) patients.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on Trovagene's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any medical diagnostic tests under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. Trovagene does not undertake an obligation to update or revise any forward-looking statement.  Investors should read the risk factors set forth in Trovagene's Form 10-K for the year ended December 31, 2011 and other periodic reports filed with the Securities and Exchange Commission.ContactsTrovagene, Inc.Strand Life Sciences Pvt Ltd.Stephen ZaniboniVikash NeelakantanChief Financial OfficerAssistant Manager – Business Operations+1 (858) 496-74+91 (80)

SOURCE Trovagene, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. TrovaGene Acquires CLIA - Certified Laboratory
2. TrovaGene, Inc. Obtains Exclusive License to Novel Mutations Associated with Prognosis and Chemotherapy Response in Leukemia
3. IntelliCell BioSciences Announces Collaborative Agreement with the University of Florida on Stem Cell and Tissue Repair Research
4. Intellect Neurosciences, Inc. to Present at Neurotech Investing and Partnering Conference
5. Regenerative Sciences Receives $2M Investment for Orthopedic Stem Cell Initiatives
6. Roche 454 Life Sciences and SoftGenetics Sign Co-Promotion Agreement for Next-Gen Sequencing Software Tools
7. Sangamo BioSciences Announces Presentations At Upcoming Investor Conferences
8. Daiichi Sankyo And Coherus BioSciences Establish Strategic Collaboration To Develop And Commercialize Biosimilar Candidates
9. Intellect Neurosciences Adds Two New Tau Programs to its Alzheimers Disease Development Pipeline
10. Sangamo BioSciences Reports First Quarter 2012 Financial Results
11. AnaptysBio Announces Antibody Discovery Partnership With Gilead Sciences
Post Your Comments:
(Date:11/24/2015)... , Nov. 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: ... in New York on Wednesday, December 2 ... Torley , president and CEO, will provide a corporate overview. ... York at 1:00 p.m. ET/10:00 a.m. PT . ... relations, will provide a corporate overview. --> th ...
(Date:11/24/2015)... Nov. 24, 2015  Clintrax Global, Inc., a worldwide provider of ... , today announced that the company has set a new quarterly ... quarter on quarter growth posted for Q3 of 2014 to Q3 ... Mexico , with the establishment of an ... --> United Kingdom and ...
(Date:11/24/2015)... 24, 2015 --> ... report released by Transparency Market Research, the global non-invasive ... CAGR of 17.5% during the period between 2014 and ... Global Industry Analysis, Size, Volume, Share, Growth, Trends and ... testing market to reach a valuation of US$2.38 bn ...
(Date:11/24/2015)... ... 24, 2015 , ... InSphero AG, the leading supplier of easy-to-use solutions for ... Aregger to serve as Chief Operating Officer. , Having joined InSphero in ... and was promoted to Head of InSphero Diagnostics in 2014. There she ...
Breaking Biology Technology:
(Date:11/12/2015)... , Nov. 11, 2015   Growing ... reliable analytical tools has been paving the way ... qualitative determination of discrete analytes in clinical, agricultural, ... are being predominantly used in medical applications, however, ... environmental sectors due to continuous emphasis on improving ...
(Date:11/9/2015)... Nov. 9, 2015  Synaptics Inc. (NASDAQ: SYNA ... announced broader entry into the automotive market with a ... the pace of consumer electronics human interface innovation. Synaptics, ... ideal for the automotive industry and will be implemented ... Europe , Japan , ...
(Date:10/29/2015)... Oct. 29, 2015 Daon, a global leader ... has released a new version of its IdentityX ... North America have already installed IdentityX ... includes a FIDO UAF certified server component ... to activate FIDO features. These customers include some of ...
Breaking Biology News(10 mins):